慢性阶段慢性髓性白血病患者的整体和经质量调整的预期寿命减少
Enoch Yi-Tung Chen1, Torsten Dahlén2,3, Leif Stenke3,4
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
European journal of haematology
|November 6, 2024
概括
患有慢性髓性白血病 (CML) 的患者经历了预期寿命 (LE) 的小损失,但质量调整后预期寿命 (LQALE) 显著减少,尽管用氨酸激酶抑制剂治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 公共卫生 公共卫生
背景情况:
- 氨酸激酶抑制剂 (TKIs) 改善了慢性髓性白血病 (CML) 患者的生存率.
- 评估与健康相关的生活质量 (HRQoL) 以及生存率对于全面的患者护理至关重要.
研究的目的:
- 量化慢性阶段CML (CP-CML) 患者与普通人群相比的预期寿命 (LLE) 和质量调整预期寿命 (LQALE) 的损失.
- 评估这些损失相对于一般人口的寿命和质量调整后的预期寿命的比例.
主要方法:
- 利用了来自瑞典CML注册的数据,包括2007-2017年间诊断的991名成年患者.
- 使用多状态模型来估计LLE和LQALE.
- 后续数据延长至2018年.
主要成果:
- 患有CP-CML的患者表现出相对较低的LLE,但明显更高的LQALE.
- 对于在45岁时被诊断的女性,LLE为5.7年,而LQALE为12.0个质量调整寿命年 (QALY).
- 在所有年龄段,LLE的比例损失在9%-15%,LQALE的比例损失在29%-33%.
结论:
- 尽管生存率有所改善,但患有CP-CML的患者面临着质量调整后生命年数显著减少.
- 这些发现凸显了对CP-CML管理的进一步进步的需要,以解决未满足的医疗需求并改善患者的整体福祉.
相关概念视频
Disorders of Leukocytes
877
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
877
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Kaplan-Meier Approach
102
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
102
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


